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expression and Role of 
Gonadotropin-Releasing Hormone 2 
and its Receptor in Mammals
Amy T. Desaulniers1, Rebecca A. Cederberg1, Clay A. Lents2 and Brett R. White1*
1 Department of Animal Science, University of Nebraska-Lincoln, Lincoln, NE, United States, 2 USDA, ARS, USMARC,  
Clay Center, NE, United States
Gonadotropin-releasing hormone 1 (GnRH1) and its receptor (GnRHR1) drive 
mammalian reproduction via regulation of the gonadotropins. Yet, a second form 
of GnRH (GnRH2) and its receptor (GnRHR2) also exist in mammals. GnRH2 has 
been completely conserved throughout 500 million years of evolution, signifying high 
selection pressure and a critical biological role. However, the GnRH2 gene is absent 
(e.g., rat) or inactivated (e.g., cow and sheep) in some species but retained in others 
(e.g., human, horse, and pig). Likewise, many species (e.g., human, chimpanzee, 
cow, and sheep) retain the GnRHR2 gene but lack the appropriate coding sequence 
to produce a full-length protein due to gene coding errors; although production of 
GnRHR2 in humans remains controversial. Certain mammals lack the GnRHR2 gene 
(e.g., mouse) or most exons entirely (e.g., rat). In contrast, old world monkeys, musk 
shrews, and pigs maintain the coding sequence required to produce a functional 
GnRHR2. Like GnRHR1, GnRHR2 is a 7-transmembrane, G protein-coupled receptor 
that interacts with Gαq/11 to mediate cell signaling. However, GnRHR2 retains a cytoplas-
mic tail and is only 40% homologous to GnRHR1. A role for GnRH2 and its receptor 
in mammals has been elusive, likely because common laboratory models lack both the 
ligand and receptor. Uniquely, both GnRH2 and GnRHR2 are ubiquitously expressed; 
transcript levels are abundant in peripheral tissues and scarcely found in regions of 
the brain associated with gonadotropin secretion, suggesting a divergent role from 
GnRH1/GnRHR1. Indeed, GnRH2 and its receptor are not physiological modulators 
of gonadotropin secretion in mammals. Instead, GnRH2 and GnRHR2 coordinate the 
interaction between nutritional status and sexual behavior in the female brain. Within 
peripheral tissues, GnRH2 and its receptor are novel regulators of reproductive organs. 
GnRH2 and GnRHR2 directly stimulate steroidogenesis within the porcine testis. 
In the female, GnRH2 and its receptor may help mediate placental function, implanta-
tion, and ovarian steroidogenesis. Furthermore, both the GnRH2 and GnRHR2 genes 
are expressed in human reproductive tumors and represent emerging targets for can-
cer treatment. Thus, GnRH2 and GnRHR2 have diverse functions in mammals which 
remain largely unexplored.
Keywords: GnRH2, GnRH2 receptor, reproductive function, G protein-coupled receptor, G protein-coupled 
receptor signal transduction, autocrine/paracrine mechanisms, testis, cancer
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BACKGROUND
The Classical Form of Mammalian 
Gonadotropin-Releasing Hormone 
(GnRH1)
The classical, hypophysiotropic GnRH1 is hailed as the master 
regulator of reproduction in mammals. GnRH1 is a decapeptide 
(pGlu–His–Trp–Ser–Tyr–Gly–Leu–Arg–Pro–Gly–NH2) 
produced by hypothalamic neurons and secreted in a pulsatile 
manner into hypophyseal portal capillaries where it travels to 
the anterior pituitary gland. GnRH1 then binds to its receptor 
(GnRHR1) on gonadotrope cells, promoting the synthesis and 
secretion of the gonadotropins, follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH), into peripheral circulation 
where they act on their target organs, the gonads. In females, FSH 
stimulates follicular development, whereas LH promotes ovula-
tion and maintenance of the corpus luteum. Within the testes, 
FSH regulates spermatogenesis and LH elicits secretion of testos-
terone. Ultimately, the gonads cease to function and reproduction 
is halted in the absence of GnRH1 (1–3).
GnRH variants in Mammals
Gonadotropin-releasing hormone 1 was first identified in the 
hypothalami of pigs and sheep (4–6) and was originally thought 
to be a novel peptide. However, 23 other forms of GnRH have 
since been discovered (7), all with 10 amino acids and at least 
a 50% sequence identity (8). Within these forms, the sequences 
of both the N-terminus (pGlu–His–Trp–Ser) and C-terminus 
(Pro–Gly–NH2) are conserved (7, 9). The amino acid substitu-
tions only occur between residues 5 and 8 (7, 9). In vertebrates, 
three forms of GnRH (GnRH1, GnRH2, and GnRH3) are the 
most common. The third form of GnRH (GnRH3; pGlu–His–
Trp–Ser–His–Asp–Trp–Lys–Pro–Gly–NH2) was first discovered 
in lamprey (10) but the GnRH3 gene has only been confirmed in 
fish and amphibians to date (7, 11). Therefore, only GnRH1 and 
GnRH2 are produced in mammals (7).
GONADOTROPiN-ReLeASiNG  
HORMONe 2
The Second Form of Mammalian GnRH 
(GnRH2)
A second structural variant of GnRH, GnRH2, has been identi-
fied in mammals. Like GnRH1, GnRH2 is a decapeptide but it 
was first isolated from the hypothalami of 10,000 chickens and 
therefore named “chicken GnRH2” (12). It was later discovered 
in mammals, the first being marsupials (13), and renamed simply 
“GnRH2” to prevent confusion (14). Since then, GnRH2 has 
been found in animals of every vertebrate class including primi-
tive orders (e.g., bony fish) as well as complex mammals (15). 
GnRH2 is absent only in jawless fish (16). Notably, the sequence 
of GnRH2 remains entirely conserved throughout evolution, 
indicating high selection pressure and a critical function (17). 
Absolute conservation of GnRH2 has persisted despite 500 mil-
lion years of evolution (15), indicating that it may be the most 
ancient form of GnRH (18). In contrast, GnRH1 evolved 350 
million years ago and its sequence varies greatly among verte-
brates (19).
The Gene for GnRH2
GnRH2 is not merely a splice variant of the GnRH1 gene; instead, 
it is produced from its own gene that encodes the peptide, prepro-
GnRH2 (20). The GnRH2 gene is located on chromosome 20 in 
humans, chimpanzees, and orangutans, chromosome 13 in the 
cow, chromosome 22 in the horse, chromosome 10 in the rhesus 
macaque, and chromosome 17 in the pig (21). The genomic orienta-
tion of the GnRH2 gene is highly conserved across species (21, 22). 
It is flanked by the PTPRA and MRPS26 genes in all mammalian 
and non-mammalian vertebrates examined to date (21, 22). The 
PTPRA gene resides about 5–6 kb upstream of the GnRH2 gene 
(21) and encodes the enzyme, receptor-type tyrosine-protein 
phosphatase α, which is critical for neural development (23). The 
MRPS26 gene resides about 300 bp downstream of the GnRH2 
gene (21), encoding mitochondrial ribosome protein S26, which 
assists in protein synthesis (24). A graphical representation of the 
porcine GnRH2 gene is depicted in Figure 1A.
The human GnRH2 gene has three coding exons like the 
GnRH1 gene; however, the GnRH2 gene is notably shorter 
(2.1 versus 5.1 kb), primarily due to differences in intron length 
(20). Otherwise, organization of the GnRH1 and GnRH2 genes 
remain similar (25). The first coding exon in humans encodes the 
signal sequence, mature decapeptide, and a portion of the GnRH-
associated peptide (GAP). The second and third exons encode 
the remaining GAP (20). Likewise, porcine prepro-GnRH2 
is encoded by 3 exons and yields a 110 amino acid product 
(Figure  1B) that must undergo post-translational proteolytic 
processing for functionality (20).
Presence of the GnRH2 Gene in Mammals
Although the GnRH2 gene was first identified in humans 
(20), Stewart et  al. (21) examined the genomes of mammals 
encompassing 10 orders for the presence of the GnRH2 gene. 
The GnRH2 gene was positively identified in 21 animals. Using 
bioinformatics, the authors concluded that gene coding errors 
likely prevent the successful production of GnRH2 in many 
species (21). A summary of the coding errors present in the 
GnRH2 gene of mammals is available in Table 1. A premature 
stop codon truncates the mature decapeptide in the chimpanzee, 
orangutan, mouse lemur, sheep, and cat (21, 26), whereas the 
rabbit, pika, cow, dog, cat, and dolphin GnRH2 genes encode 
an inactive peptide (21, 26). Early evidence implied that the rat 
and mouse also maintain a GnRH2 gene as immunoreactive 
GnRH2 was detected in the rodent brain (27–29). Although it 
was later determined that the mouse genome only maintains a 
fragment of the GnRH2 gene (exon 1) on chromosome 2 and it 
is completely deleted from chromosome 3 in the rat (21, 22, 30). 
Together, these data reveal that the GnRH2 gene is absent or 
functionally inactivated in many mammals. In contrast, 10 
species (human, macaque, marmoset, tarsier, tree shrew, guinea 
pig, musk shrew, common shrew, horse, and pig) maintain the 
appropriate genomic sequence to produce a biologically active 
FiGURe 1 | Genomic organization of the porcine GnRH2 gene and its products. (A) The PTPRA gene (green) is located 6.1 kb upstream, whereas the MRPS26 
gene (red) is positioned 278 bp downstream of the porcine GnRH2 gene (blue) on chromosome 17. Arrows indicate start codons for each gene. (B) The porcine 
GnRH2 gene contains three coding exons and two introns. Exon 1 (~150 bp) of the porcine GnRH2 gene encodes the signaling sequence (SS), mature GnRH2 
decapeptide, and a portion of the GnRH-associated peptide (GAP). Exon 2 (~140 bp) and exon 3 (~40 bp) encode the remaining GAP sequence. Note that introns 
and exons are not drawn to scale. (C) Amino acid sequence alignments of predicted porcine prepro-GnRH2 isoforms (NCBI accession numbers XP_005672842 
and XP_013840618) with porcine prepro-GnRH1 (NCBI accession number NP_999439). Prepro-GnRH1 is 91 amino acids in length compared with prepro-GnRH2, 
which has 110 residues. An isoform of prepro-GnRH2 (143 amino acids) is also predicted to be produced from the porcine GnRH2 gene due to alternative splicing. 
The amino acids that correspond to the SS, the mature decapeptide, and the GAP are indicated. The proteolytic cleavage sites are highlighted in bold.
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decapeptide (21). We re-evaluated the presence of the GnRH2 
gene in mammals by surveying updated NCBI gene databases 
and found that an additional 68 mammals, comprising 9 addi-
tional orders, possess the GnRH2 gene to date (Table 2). Thus, 
89 mammals from 19 orders maintain the GnRH2 gene, further 
suggesting that the GnRH2 gene was present in a common 
mammalian ancestor (21). However, whether the GnRH2 gene 
encodes a functional peptide in all of these animals remains 
unknown.
GnRH2 is Ubiquitously expressed within 
Mammals
Like GnRH1, GnRH2 has been identified in the pre-optic 
and medio-basal hypothalamic areas (7), albeit scarcely (33). 
Likewise, our group detected low levels of GnRH2 within the 
hypothalamus of the pig, implying that GnRH2 is not a promi-
nent regulator of gonadotropin secretion (34, 35). GnRH2 has 
also been discovered in the midbrain and limbic structures, 
suggesting a role in the modulation of reproductive behavior 
(14, 29). In primates and humans, GnRH2 is prevalent in the 
caudate nucleus, hippocampus, and amygdala (36, 37) and has 
also been detected in the midbrain and hindbrain (7). White 
et  al. (20) quantified expression of the GnRH2 gene in 50 dif-
ferent human tissues, including numerous regions of the brain 
(20). Surprisingly, GnRH2 mRNA was identified in all tissues 
examined and levels were highest in peripheral tissues; the 
converse was true for GnRH1.
In the periphery, transcript levels for GnRH2 were 30-fold 
higher in the kidney and 4-fold higher in bone marrow and the 
prostate compared with the brain. GnRH2 is also produced in 
organs of the thoracic (e.g., heart, lung, and aorta), digestive (e.g., 
salivary gland, stomach, and intestine), endocrine (e.g., adrenal, 
pancreas, and thyroid), and immune (e.g., tonsil, leukocyte, and 
lymph node) systems (Table 3) (11, 29). Moreover, GnRH2 has 
been identified in numerous female (e.g., ovary, uterus, endo-
metrium, and myometrium) and male (e.g., testis, epididymis, 
seminal vesicles, and prostate) reproductive organs (Table  3) 
(11, 29). The ubiquitous nature of this decapeptide is also 
TABLe 1 | Presence and potential functionality of the GnRH2 and GnRHR2 genes within mammals.a
Order Mammal (genus species) GnRH2 GnRHR2
Gene Coding disruptionb Functional 
protein
Gene Coding disruptionb Functional 
protein
Artiodactyla Alpaca (Vicugna pacos) + ? ? + ? ?
Cow (Bos taurus) + AAA − + PSC −
Pig (Sus scrofa) + − + + − +
Sheep (Ovis aries) + PSC − + PSC −
Carnivora Cat (Felis catus) + PSC; FM; AAA − + PSC −
Dog (Canis familiaris) + PSC; AAA − + PSC; FM −
Cetacea Bottle-nosed dolphin (Tursiops truncatus) + AAA − + FM; AAA; PSC −
Lagomorpha Pika (Ochotona princeps) + AAA; BI − ? ? ?
Rabbit (Oryctolagus cuniculus) + MS; PSC − + MS; FM; PSC −
Perissodactyla Horse (Equus caballus) + − + + FM; PSC −
Primates African green monkey (Cercopithecus aethiops) ? ? ? + − +
Chimpanzee (Pan troglodytes) + PSC − + FM; PSC −
Common marmoset (Callithrix jacchus) + − + + − +
Human (Homo sapien) + − + + FM; PSC −
Mouse lemur (Microcebus murinus) + PSC − + ? ?
Orangutan (Pongo pygmaeus) + PSC − + − +
Rhesus macaque (Macaca mulatta) + − + + − +
Tarsier (Tarsius syrichta) + − + + ? ?
Proboscidea African elephant (Loxodonta africana) + ? ? + − +
Rodentia Ground squirrel (Spermophilus tridecemlineatus) + ? ? + PSC; AAA −
Guinea pig (Cavia porcellus) + − + + PSC; FM −
Kangaroo rat (Dipodomys ordii) + ? ? + AAA ?
Mouse (Mus musculus) + GR − − − −
Rat (Rattus norvegicus) − − − + GR −
Scandentia Tree shrew (Tupaia belangeri) + − + + − +
Soricomorpha Common shrew (Sorex araneus) + − + + BD; FM; PSC −
Musk shrew (Suncus murinus)c + − + ? ? +
aData are based on bioinformatics. Absence of the gene or functional protein is denoted by a (−), whereas presence is indicated by a (+). Species in which there was not enough 
genomic information available (or the functionality has not yet been assessed) will be noted as a (?). Adapted from Stewart et al. (21).
bIn many species, the gene for GnRH2 and/or GnRHR2 is present but presumed non-functional due to gene coding errors. If the gene is affected, the nature of the disruption is 
indicated. Absence of a gene disruption is indicated by a minus symbol (−).
cThe genome of the musk shrew has not been fully annotated. Therefore, the presence of GnRHR2 in the musk shrew is putative based on the work of Temple et al. (31) and 
Kauffman et al. (32) establishing a functional GnRHR2.
Abbreviations: PSC, premature stop codon; FM, frameshift mutation; AAA, amino acid alteration; GR, gene remnant; BI, base insertion; BD, base deletion; MS, missing sequence.
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evident in the many immortalized cell lines in which GnRH2 
has been isolated, including cells derived from breast tissue 
(38), lymphocytes (39), ovaries (40, 41), and neural tissue (42). 
A summary of the mammalian cell lines that produce GnRH2 
is available in Table 4. Ultimately, these data demonstrate that 
GnRH2 is ubiquitously expressed, indicating a divergent func-
tion from GnRH1.
Transcriptional Regulation of GnRH2 Gene 
expression
The expression of GnRH2 is regulated by several different 
reproductive hormones including androgens, 17β-estradiol, 
progesterone, the gonadotropins, and GnRH2 itself. Darby et al. 
(54) demonstrated in tumors from prostate cancer patients that 
androgens enhance GnRH2 expression. This effect was likely 
mediated at the transcriptional level because sequence analysis 
of the 5′ flanking region for the human GnRH2 gene revealed 
the presence of a putative androgen response element and 
direct interaction with the androgen receptor was confirmed 
via chromatin immunoprecipitation assays (54). In females, 
GnRH2 expression in the hypothalamus of rhesus macaques 
is stimulated by 17β-estradiol treatment (55). Similarly, 
treatment of human granulosa-luteal cells with 17β-estradiol 
resulted in a dose-dependent increase in GnRH2 mRNA 
expression (56) and 17β-estradiol exerted a stimulatory effect 
on GnRH2 expression in human neuronal cells (42). The effect 
of progesterone has also been examined in humans. Primary 
cultures of human granulosa-luteal cells treated with RU486 
(progesterone receptor antagonist) increased GnRH2 expres-
sion in a time- and dose-dependent fashion (56). However, 
neither progesterone nor RU486 affected GnRH2 expression in 
human neuronal cells (57).
There is also evidence that protein hormones modulate 
GnRH2 production. Treatment with FSH or human chorionic 
gonadotropin (hCG) upregulated GnRH2 gene transcription 
Order Common name Genus species NCBi gene 
iD
Green monkey Chlorocebus sabaeus 103247081
Ma’s night monkey Aotus nancymaae 105711412
Northern white-
cheeked gibbon
Nomascus leucogenys 100594202
Olive baboon Papio anubis 100997952
Pig-tailed macaque Macaca nemestrina 105481609
Pygmy chimpanzee Pan paniscus 100971926
Sooty mangabey 
monkey
Cercocebus atys 105582156
Sumatran orangutan Pongo abelii 100441160
Sunda flying lemur Galeopterus variegatus 103588840
Western gorilla Gorilla gorilla 101151325
White-headed 
capuchin monkey
Cebus capucinus 
imitator
108286755
White-tufted-ear 
marmoset
Callithrix jacchus 103792807
Proboscidea African elephant Loxodonta africana 100668639
Rodentia Alpine marmot Marmota marmota 
marmota
107143918
American beaver Castor canadensis 109686520
Damara mole-rat Fukomys damarensis 104853177
Degu Octodon degus 101565240
Kangaroo rat Dipodomys ordii 105981455
Long-tailed chinchilla Chinchilla lanigera 102005135
Naked mole-rat Heterocephalus glaber 101717034
Thirteen-lined ground 
squirrel
Spermophilus 
tridecemlineatus
101971577
Scandentia Chinese tree shrew Tupaia chinensis 102500815
Tubulidentata Aardvark Orycteropus afer afer 103191804
TABLe 2 | Identification of the GnRH2 gene within 68 additional mammals via 
NCBI gene database queries.
Order Common name Genus species NCBi gene 
iD
Afrosoricida Cape golden mole Chrysochloris asiatica 102818594
Artiodactyla Alpaca Vicugna pacos 102537645
Arabian camel Camelus dromedarius 105096036
Bactrian camel Camelus bactrianus 105083071
Bison Bison bison bison 104986175
Goat Capra hircus 102171992
Texas white-tailed 
deer
Odocoileus virginianus 
texanus
110145856
Tibetan antelope Pantholops hodgsonii 102339298
Water buffalo Bubalus bubalis 102408995
Wild bactrian camel Camelus ferus 102511575
Wild yak Bos mutus 102280393
Zebu cattle Bos indicus 109567205
Carnivora Amur tiger Panthera tigris altaica 102950818
Cheetah Acinonyx jubatus 106980160
Ferret Mustela putorius furo 101672225
Giant panda Ailuropoda melanoleuca 100469838
Leopard Panthera pardus 109274781
Pacific walrus Odobenus rosmarus 
divergens
101378339
Polar bear Ursus maritimus 103674386
Weddell seal Leptonychotes weddellii 102734468
Cetacea Killer whale Orcinus orca 101276573
Minke whale Balaenoptera 
acutorostrata scammoni
103020677
Sperm whale Physeter catodon 102986533
Yangtze river dolphin Lipotes vexillifer 103085292
Chiroptera Big brown bat Eptesicus fuscus 103285836
Brandt’s bat Myotis brandtii 102246670
Chinese rufous 
horseshoe bat
Rhinolophus sinicus 109448424
Little brown bat Myotis lucifugus 102433482
Myotis davii bat Myotis davii 102763285
Dasyuromorphia Tasmanian devil Sarcophilus harrisii 100916503
Didelphimorphia Gray short-tailed 
opossum
Monodelphis domestica 103098126
Diprotodontia Koala Phascolarctos cinereus 110221117
Erinaceomorpha Western European 
hedgehog
Erinaceus europaeus 103128681
Eulipotyphla Star-nosed mole Condylura cristata 101633945
Macroscelidea Cape elephant shrew Elephantulus edwardii 102862182
Perissodactyla Donkey Equus asinus 106844450
Przewalski’s horse Equus przewalskii 103555821
Southern white 
rhinoceros
Ceratotherium simum 
simum
106802382
Primate Angolan colobus Colobus angolensis 105512752
Black snub-nosed 
monkey
Rhinopithecus bieti 108529998
Bolivian squirrel 
monkey
Saimiri boliviensis 101028145
Coquerel’s sifaka 
monkey
Propithecus coquereli 105827546
Crab-eating macaque Macaca fascicularis 102124425
Drill Mandrillus leucophaeus 105535577
Golden snub-nosed 
monkey
Rhinopithecus roxellana 104674617
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(Continued )
TABLe 2 | Continued
in granulosa-luteal cells of humans (58). Likewise, GnRH2 
mRNA and protein levels increased in human neuronal cells 
in response to cAMP treatment, a downstream messenger 
of the gonadotropins (59). This effect probably occurs at the 
transcriptional level given that mutation of a putative cAMP-
responsive element in the 5′ flanking sequence of the human 
GnRH2 gene suppressed activity of the GnRH2 promoter (59). 
However, when normal and cancerous ovarian cells were 
treated with LH and FSH, GnRH2 expression was reduced in 
the majority of cell lines tested; only CaOV-3 and SKOV-3 cells 
were unaffected by treatment, despite expression of receptors 
for the gonadotropins (47). GnRH2 may mediate its own 
expression in an autocrine/paracrine manner. For example, 
granulosa cells secrete GnRH2 (60) and culture of human 
granulosa-luteal cells for 10  days increased GnRH2 mRNA 
expression (56). A different study demonstrated that treat-
ment of luteinized granulosa cells with GnRH2 downregulated 
GnRH2 expression (58).
Prepro-GnRH2
The porcine prepro-GnRH2 is only 56% homologous to 
prepro-GnRH1 (NCBI accession numbers XP_005672842 and 
NP_999439, respectively) but contains the same components: 
a signal sequence, the decapeptide, a conserved cleavage 
site, and GAP (20). As with all peptide hormones, the signal 
Tissue or cell 
type
GnRH2 GnRHR2 Reference
identifiedb Species identifiedb Species
Male reproductive
Testis + h, p + h, m, p (11, 20, 29, 
35, 45)
Leydig cells + p + p (35, 45)
Sertoli cells + p + p (35, 45)
Germ cells + p + h, p (35, 45, 46)
Spermatozoa + h, p (34, 45, 46)
Epididymis + p + m, p (29, 34)
Seminal vesicles + p + m, p (29, 34)
Bulbourethral + p + p (34)
Prostate + h, p + h, m, p (11, 20,  
29, 34)
aAdapted from Millar (16). Blank cells indicate tissues that have not yet been  
examined.
bEither mRNA or protein was discovered.
cSee Millar (16) for specific regions of the brain that produce GnRH2 and/or GnRHR2.
Abbreviations: +, positive; −, negative; p, pig; h, human; m, marmoset; r, rhesus 
macaque.
TABLe 3 | Production of GnRH2 and GnRHR2 in mammalian tissues.a
Tissue or cell 
type
GnRH2 GnRHR2 Reference
identifiedb Species identifiedb Species
Central nervous system
Brain (whole) + h + h (11, 20, 29)
Forebrainc + h, r + h, r, m (16, 20, 29)
Midbrainc + h, r + h, r, m (16, 20, 29)
Hindbrainc + r + h, r, m (16, 20, 29)
Spinal cord + h + h, m (20, 29)
endocrine
Hypothalamus + p + m (29, 35)
Pituitary (whole) + h + m, h (11, 20, 29)
Anterior pituitary + p + p (35)
Adrenal gland + h + h, m (11, 20, 29)
Pancreas + h + h, m (16, 20, 29)
Thyroid + h + h, m (11, 20, 29)
Thoracic
Heart + h + h, m (11, 16,  
20, 29)
Aorta + h (20)
Lung + h + h, m (11, 20, 29)
Thymus gland + h + h, m (11, 20, 29)
Trachea + h (20)
Digestion and metabolism
Salivary gland + h (20)
Stomach + h + h, m (11, 20, 29)
Small intestine + h + h (11, 20)
Duodenum − h (43)
Jejunum + h (43)
Ileum + h (43)
Large intestine + h + h (11, 20)
Cecum + h (43)
Colon − h (43)
Rectum − h (43)
Liver + h + h, m (11, 16,  
20, 29)
Skeletal muscle + h + m, h (11, 16,  
20, 29)
Renal
Bladder + h + m (20, 29)
Kidney + h + h, m (11, 16,  
20, 29)
immune
Peripheral 
leukocyte
+ h (20)
T lymphocyte + h (39)
Lymph node + h (20)
Tonsil + h (20)
Bone marrow + h (20)
Spleen + h + h, m (11, 20, 29)
Female reproductive
Ovary + h + h, m (11, 20, 29)
Ovarian surface 
epithelial cells
+ h (40, 41)
Granulosa cells + h (41)
Oviduct + m (29)
Uterus + h + h, m (11, 20, 29)
Endometrium + h (20)
Myometrium + h + h (44)
Breast/mammary + h + h, m (11, 20,  
29, 38)
Placenta + h + h (11, 20)
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(Continued )
TABLe 3 | Continued
sequence directs the hormone to the secretory pathway (61). 
Interestingly, the signal sequence of prepro-GnRH1 and 
prepro-GnRH2 are dissimilar in the pig (Figure  1C). This 
distinction could be important because composition of the 
signal sequence has been reported to influence the efficiency 
of secretion (61). The cleavage site (Gly–Lys–Arg) is conserved 
between prepro-GnRH2 and prepro-GnRH1 (Figure  1C), 
indicating that carboxypeptidase E, the enzyme responsible 
for cleaving GnRH1 from GAP in mice (62), likely processes 
prepro-GnRH2 as well.
To date, the GAP of prepro-GnRH2 has not been studied 
directly. However, the GAP of prepro-GnRH1 is secreted with the 
mature decapeptide (63) and has been associated with prolactin 
and gonadotropin secretion (64, 65). Prepro-GnRH1 and prepro-
GnRH2 in the human have similar lengths except the GAP, which 
is 50% longer in prepro-GnRH2 (20). Porcine prepro-GnRH2 
(110 amino acids) is also longer than prepro-GnRH1 (91 amino 
acids), primarily due to a longer GAP (73 versus 55 amino acids, 
respectively; Figure 1C). A similar result was also reported for the 
tree shrew (66), indicating that a longer GAP in prepro-GnRH2 
may be common in mammals (20) and could have functional 
relevance.
Notably, White et  al. (20) reported the presence of two 
GnRH2-GAP variants in humans. Certain tissues (e.g., fetal 
brain and thalamus) expressed a longer GAP variant than others 
(e.g., kidney) (20). Likewise, Cheon et al. (67) discovered two tran-
script variants of GnRH2 with differing GAP lengths in the endo-
metrium of women. The porcine GnRH2 gene is also predicted 
to produce two forms of prepro-GnRH2. The classical product 
is 110 amino acids (NCBI accession number XP_005672842), 
whereas the splice variant encodes a 143 amino acid isoform 
(NCBI accession number XP_013840618), due to the retention 
of intron 2. The only differences between the two products were 
detected in the GAP region (Figure 1C). Although, the biological 
significance of these variants of GAP for prepro-GnRH2 has not 
yet been elucidated.
TABLe 4 | Production of GnRH2 and GnRHR2 in mammalian cell lines.
Cell line Origin Species GnRH2a GnRHR2a Reference
Nervous
TE671 Neuronal medulloblastoma Human + (41)
Lung
A549 Alveolar adenocarcinoma Human + (11)
Digestive
SW480 Colorectal adenocarcinoma Human + (11)
IPEC-J2 Intestinal epithelial cells Porcine + (48)
immune
HL-60 Promyelocytic leukemia Human + (11)
Jukat T cell leukemia Human + + (39, 49)
Mammary
MDAMB-231 Breast adenocarcinoma Human + (38)
MCF-7 Breast adenocarcinoma Human + (38)
MCF-10A Breast epithelium Human + (38)
Female reproductive
HeLa Cervical adenocarcinoma Human + (11, 50)
Hec-1A Endometrial adenocarcinoma Human + (51)
Hec-1B Endometrial adenocarcinoma Human (52)
Ishikawa Endometrial adenocarcinoma Human + (51)
HHUA Endometrial adenocarcinoma Human + (49)
EFO-21 Ovarian cystadenocarcinoma Human + (51)
EFO-27 Ovarian adenocarcinoma Human − (52)
OVCAR-3 Ovarian adenocarcinoma Human + + (40, 51)
SK-OV-3 Ovarian adenocarcinoma Human + + (40, 51)
CaOV-3 Ovarian adenocarcinoma Human + (40)
BG-1 Ovarian adenocarcinoma Human + + (47, 52)
IOSE-29 Ovarian surface epithelia Human + (40)
SVOG-4O Granulosa-luteal cells Human + (41)
SVOG-4m Granulosa-luteal cells Human + (41)
Male reproductive
ST Fetal testis Porcine + (53)
ALVA-41 Prostate adenocarcinoma Human + (50)
PPC-1 Prostate adenocarcinoma Human + (50)
DU-145 Prostate carcinoma Human + (49, 50)
Urinary
TSU-Pr1 Bladder carcinoma Human + (49, 50)
COS-1b Kidney African green monkey + (11)
HEK293 Embryonic kidney Human + (50)
aThe presence of a (+) indicates that either mRNA or protein has been identified, whereas a (−) specifies that the tissue was negative. Blanks designate cell lines that have not yet 
been examined.
bThe presence of GnRHR2 protein is putative as GnRH2 treatment of COS-1 cells yielded IP accumulation.
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and half-life (71, 72) compared with GnRH1, which is rapidly 
degraded (73).
GONADOTROPiN-ReLeASiNG HORMONe 
2 ReCePTOR
identification of GnRHR2 in Mammals
Originally cloned in African catfish (74), a 7-transmembrane 
(TM) G protein-coupled receptor (GPCR) specific to GnRH2 
(GnRHR2) has also been discovered in mammals (11, 29). The 
GnRHR2 gene was first identified in mammals by surveying 
the human genome for genes with high homology to GnRHR1  
(11, 29). A gene with 40% homology to GnRHR1 was identified 
The Structure of GnRH2
GnRH2 (pGlu–His–Trp–Ser–His–Gly–Trp–Tyr–Pro–Gly–NH2) 
differs from GnRH1 by three amino acids [His5, Trp7, and 
Tyr8; (12)], resulting in 70% sequence identity (20). Amino 
acids His5, Trp7, and Tyr8 help stabilize GnRH2, whereas the 
N-terminal (pGlu1, His2, Trp3, and Ser4) and C-terminal (Pro9, 
Gly–NH210) residues are essential for receptor binding and 
activation (68). Structurally, GnRH2 is more negatively charged 
and slightly bulkier than GnRH1 (30). GnRH2 has a β-turn 
conformation that is similar to GnRH1; however, GnRH2 
exists in a preconfigured conformation. Thus, GnRH2 does not 
require extensive conformational changes for receptor activation 
(68). The conformation of GnRH2 may render it less sensitive 
to peptidases (69), likely increasing (6-fold) its stability (70) 
FiGURe 2 | Genomic organization of the porcine GnRHR2 gene on chromosome 4. (A) The PEX11B gene (green) is located 616 bp upstream, whereas the RBM8A 
gene (red) is positioned 423 bp downstream of the GnRHR2 gene (blue). Arrows indicate start codons for each gene. Reprinted from Brauer et al. (75) with 
permission from Elsevier. (B) The GnRHR2 gene contains 3 coding exons and 2 introns, yielding a 377 amino acid product. Exon 1 of the porcine GnRHR2 gene 
encodes the extracellular N-terminus (NT), transmembrane (TM) domains 1–3, part of TM4, intracellular loops (ICL) 1–2 and extracellular loop (ECL) 1. Exon 2 
encodes the remainder of TM4 as well as TM5, ECL2, and part of ICL3. Exon 3 encodes the remainder of ICL3, TM domains 6–7, ECL3, and the C-terminal tail 
(CT). Note that introns and exons are not drawn to scale.
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but it was more similar to GnRHR2 in fish (65% identity) and 
amphibians (55% identity), suggesting the identification of a 
human GnRHR2 gene (11). Mammals only maintain genes for 
GnRHR1 and GnRHR2, although a GnRHR3 gene has been 
discovered in other vertebrates (16).
The Gene for GnRHR2
The human, chimpanzee, and rhesus macaque GnRHR2 gene is 
located on chromosome 1 (21). In other species, however, the 
gene for GnRHR2 is located on chromosome 17 (dog), chromo-
some 5 (horse), chromosome 3 [cow; (21)], and chromosome 
4 [pig; (21, 75)]. The GnRHR2 gene is closely associated in the 
antisense orientation with the RBM8A and PEX11B genes in all 
species (21, 22, 76). In humans, the promoter regions of GnRHR2 
and PEX11B overlap and the 3′ untranslated region (UTR) of 
RBM8A overlaps with two exons of the GnRHR2 gene (76, 77). 
The RBM8A gene encodes RNA-binding motif protein 8A, which 
helps modulate the post-translational regulation of gene expres-
sion (78) and the PEX11B gene codes for peroxisomal membrane 
protein 11β, which is involved in the regulation of peroxisome 
abundance (79). In the pig, the RBM8A gene is located 423 bp 
downstream of the GnRHR2 gene (Figure 2A). The 3′ UTRs of 
these two genes overlap, in opposite orientation on complemen-
tary strands. Upstream of the GnRHR2 gene, the PEX11B gene is 
also located on the antisense strand in the opposite orientation 
(Figure 2A). The proximal promoters of these two genes overlap, 
with start codons 616 bp apart (75).
The porcine GnRHR2 gene has three exons and two introns 
(Figure  2B). Exon 1 (530  bp) of the porcine GnRHR2 gene 
encodes the extracellular N-terminus, TM domains 1–3, part 
of TM domain 4, intracellular loop (ICL) 2, and extracellular 
loop (ECL) 1. Exon 2 (215 bp) encodes the remainder of TM4 as 
well as TM5, ECL2, and part of ICL3. Exon 3 (450 bp) encodes 
the remainder of ICL3, TM6–7, ECL3, and the C-terminal tail 
(Figure 2B). Intron 1 of the porcine GnRHR2 gene is relatively 
large (2.8  kb) compared with intron 2 (470  bp; Figure  2B), 
similar to reports from other species (21).
An additional truncated GnRHR2 gene has also been 
discovered on chromosome 14 in humans (80), containing 
only exons 2 and 3 (46). Interestingly, exons 2 and 3 of this 
apparent pseudogene are 100% identical to the corresponding 
exons of the complete GnRHR2 gene on chromosome 1 (80). 
This distinction may be especially critical when designing 
primers/probes for analysis of GnRHR2 gene expression in 
human tissues. The truncated GnRHR2 gene (chromosome 14) 
is more transcriptionally active and widely expressed than 
the full-length gene [chromosome 1; (46)]. This could explain 
discrepancies in GnRHR2 mRNA levels of human tissues across 
studies performed prior to this finding; Neill et al. (11) utilized 
a riboprobe specific to exon 3, whereas Millar et al. (29) used 
a DNA probe specific to exon 1 (46). Consistent with the full-
length gene on chromosome 1, this truncated GnRHR2 gene is 
flanked by RBM8A, indicating it was duplicated from the chro-
mosome 1 locus via retrotransposition (77). In fact, transcripts 
TABLe 5 | Identification of the GnRHR2 gene within 61 additional mammals via 
NCBI gene database queries.
Order Common name Genus species NCBi gene 
iD
Afrosoricida Cape golden mole Chrysochloris asiatica 102817241
Lesser hedgehog 
tenrec
Echinops telfairi 101659402
Artiodactyla Alpaca Vicugna pacos 102526131
Arabian camel Camelus dromedaries 10510588
Bactrian camel Camelus bactrianus 105079482
Bison Bison bison bison 104983739
Goat Capra hircus 102184212
Texas white-tailed 
deer
Odocoileus virginianus 
texanus
110144360
Wild bactrian camel Camelus ferus 102518691
Wild yak Bos mutus 102266467
Zebu cattle Bos indicus 109555832
Carnivora Amur tiger Panthera tigris altaica 102969203
European domestic 
ferret
Mustela putorius furo 101687337
Giant panda Ailuropoda melanoleuca 100484454
Pacific walrus Odobenus rosmarus 101379215
Polar bear Ursus maritimus 103678407
Weddell seal Leptonychotes weddellii 102742574
Cetacea Killer whale Orcinus orca 101271242
Minke whale Balaenoptera 
acutorostrata scammoni
103006588
Sperm whale Physeter catodon 102982977
Yangtze river dolphin Lipotes vexillifer 103074337
Cingulata Nine-banded 
armadillo
Dasypus novemcinctus 101438616
Dasyuromorphia Tasmanian devil Sarcophilus harrisii 100925975
Didelphimorphia Gray short-tailed 
opossum
Monodelphis domestica 100014969
Diprotodontia Koala Phascolarctos cinereus 110219988
Erinaceomorpha Western European 
hedgehog
Erinaceus europaeus 103127802
Eulipotyphla Star-nosed mole Condylura cristata 101623053
Macroscelidea Cape elephant shrew Elephantulus edwardii 102866982
Perissodactyla Donkey Equus asinus 106847655
Przewalski’s horse Equus przewalskii 103556230
Southern white 
rhinoceros
Ceratotherium simum 
simum
101400748
Pholidota Malayan pangolin Manis javanica 108400376
Primates Angolan colobus Colobus angolensis 105518331
Black snub-nosed 
monkey
Rhinopithecus bieti 108531432
Bolivian squirrel 
monkey
Saimiri boliviensis 101045352
Coquerel’s sifaka 
monkey
Propithecus coquereli 105809593
Crab-eating 
macaque
Macaca fascicularis 102142398
Drill Mandrillus leucophaeus 105550280
Golden snub-nosed 
monkey
Rhinopithecus roxellana 104671044
Green monkey Chlorocebus sabaeus 103225877
Ma’s night monkey Aotus nancymaae 105730634
Mouse lemur Microcebus murinus 109730387
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of this truncated gene contain exon 2 and 3, retain intron 2, 
and also include the 3′ UTR of RBM8A, except in the antisense 
orientation (46). Likewise, the genome of the African elephant 
contains a GnRHR2 pseudogene with several point mutations/
deletions and lacking exon 1 (21).
Presence of the GnRHR2 Gene in 
Mammals
Using bioinformatics, the GnRHR2 gene was identified in the 
genomes of 22 mammalian species, although sequence analysis 
revealed that gene disruptions occurred in 12 of these species 
[Table  1; (21)]. Early evidence implied that the GnRHR2 gene 
was functional in the human, sheep, and mouse as immunostain-
ing for GnRHR2 was detected in brain tissue of these species 
(29). However, the ovine GnRHR2 gene contains a premature 
stop codon in exon 1 and a 51 bp deletion in exon 2, prevent-
ing translation of a full-length protein (26, 81). In humans (and 
chimpanzees), a frameshift mutation occurs due to a missing 
nucleotide (compared with the marmoset) in the 5′ flanking 
sequence. A premature stop codon is also present due to a single 
base change in an arginine codon in exon 2 (26, 81). Furthermore, 
the GnRHR2 gene was subsequently determined to be absent 
from chromosome 3 in the mouse genome (21, 22) and only a 
remnant of exon 1 remains on chromosome 2 in the rat (22, 30). 
In other species, the GnRHR2 gene likely encodes a non- 
functional protein as well. The bovine GnRHR2 gene is disrupted 
by frameshift mutations in all three exons, in addition to prema-
ture stop codons in exons 2 and 3 (26). The squirrel GnRHR2 gene 
contains a premature stop codon and an amino acid substitution, 
whereas the guinea pig has frameshift mutations in all three exons 
and two premature stop codons in exon 3 (21). The rabbit gene 
has a 14 bp deletion that results in a frame shift and premature 
stop codon, and the cat gene has a premature stop codon (21). 
In addition, the GnRHR2 genes in the common shrew, dolphin, 
horse, and dog harbor several frameshifts and premature stop 
codons (21). In fact, only eight species (orangutan, African green 
monkey, rhesus macaque, marmoset, tree shrew, kangaroo rat, 
pig, and elephant) possess the appropriate gene sequence to 
produce a functional GnRHR2 [Table 1; (21)].
Our laboratory surveyed the updated NCBI gene databases 
to re-evaluate which mammals maintain the GnRHR2 gene. The 
GnRHR2 gene was confirmed in the genomes of 61 additional 
species representing 11 more orders (Table  5). Based on this 
report and Stewart et  al. (21), the gene for GnRHR2 is present 
in the genomes of 83 species to date, encompassing 22 different 
mammalian orders. However, it is unclear if the gene is functional 
or silenced in these animals. Therefore, future bioinformatics 
work is needed to examine the characteristics of the GnRHR2 
gene within these species.
Coupled with the aforementioned GnRH2 gene distribution 
data, it is clear that few mammalian species have a functional 
GnRH2–GnRHR2 system. The maintenance of only part of the 
system in some species (e.g., ligand or receptor only) assumes 
interaction with the GnRH1–GnRHR1 system to maintain 
functionality. Millar et  al. (18) proposed that the presence 
of GnRH2, but not a functional GnRHR2, in some species (Continued )
Order Common name Genus species NCBi gene 
iD
Northern white-
cheeked gibbon
Nomascus leucogenys 100593225
Olive baboon Papio anubis 101008793
Pig-tailed macaque Macaca nemestrina 105479042
Pygmy chimpanzee Pan paniscus 100995783
Small-eared galago Otolemur garnettii 100963950
Sooty mangabey 
monkey
Cercocebus atys 105592861
Sumatran orangutan Pongo abelii 100460080
Sunda flying lemur Galeopterus variegatus 103595864
Tarsier Tarsius syrichta 103268450
Western gorilla Gorilla gorilla 101137503
White-headed 
capuchin monkey
Cebus capucinus 
imitator
108293668
White-tufted-ear 
marmoset
Callithrix jacchus 100399755
Rodentia Alpine marmot Marmota marmota 
marmot
107160395
American beaver Castor canadensis 109682308
Damaraland mole rat Fukomys damarensis 104865794
Degu Octodon degus 101580342
Naked mole-rat Heterocephalus glaber 101703276
Scandentia Chinese tree shrew Tupaia chinensis 102498810
Sirenia Florida manatee Trichechus manatus 
latirostris
101357387
Tubulidentata Aardvark Orycteropus afer afer 103203244
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human cancer cells with reduced GnRHR1 levels, GnRH2 (not 
GnRH1) retained the ability to inhibit cell proliferation (52). 
Small interfering RNA targeting GnRHR1 inhibited the actions 
of GnRH1 on trophoblast invasion, but GnRH2-mediated effects 
persisted (84). GnRH1 and GnRH2 also have differing effects 
in primary cultures of human decidual stromal cells; GnRH1 
increased whereas GnRH2 suppressed mRNA and protein levels 
(83). Although the results of the latter study could be related 
to divergent signaling of GnRH2 at the GnRHR1, these data 
ultimately support the presence of a functional GnRHR2 in 
humans.
Many hypotheses have arisen for how the disrupted GnRHR2 
gene may retain functionality including: (1) counteractive shifts 
in the reading frame, (2) recoding of stop codons, (3) alternative 
splicing, (4) alternative protein translation, or (5) production 
and functionality of GnRHR2 fragments (82). The mechanisms 
that could potentially yield a functional receptor from a seem-
ingly non-translatable mRNA sequence were reviewed by Neill 
et al. (82). First, a corrective shift in the reading frame, albeit 
rare, has been demonstrated in eukaryotes, allowing for the 
production of a full-length protein (85). Indeed, Millar et al. (18) 
isolated human GnRHR2 transcripts missing the stop codon. 
Second, the use of an alternative start codon (e.g., GUG instead 
of AUG) has also been considered. In humans, a GUG codon is 
downstream of the frameshift and would yield a 5-TM receptor 
with a truncated (22 amino acids) N-terminus. Interestingly, a 
similar phenomenon occurs in the translation of African green 
monkey GnRHR2 mRNA (11, 21, 82). Furthermore, the GUG 
codon within the human transcript meets the two Kozak criteria 
necessary for an alternative start codon (86, 87). Third, it has been 
proposed that the premature stop codon may be recoded (82), 
which occurs in mammals (85, 88, 89). In the human GnRHR2 
mRNA transcript, the premature stop codon is UGA but this 
codon can also encode for the amino acid, selenocysteine, 
potentially preventing the termination of translation (16, 46, 
76, 80). However, attempts to identify selenocysteine incorpora-
tion thus far have been fruitless (76). Moreover, alternative splic-
ing in exon 1 would yield a 5-TM GnRHR2 transcript without 
the reading frame disruption near the N-terminus of the 7-TM 
isoform (82). The premature stop codon, however, would still be 
present. Therefore, translation of 5-TM receptor mRNA would 
also require a stop codon read-through. A fourth hypothesis is 
that fragments of both the 5- and 7-TM isoforms are produced 
and reassociate non-covalently after translation, a characteristic 
that has been shown with other GPCRs, including GnRHR1 
(90–92). Data from Grosse et  al. (92) showed that two coex-
pressed GnRHR1 fragments (corresponding to TM domains 
1–5 and 6–7) reassociated to produce a full-length, functional 
receptor. If protein fragments of the 7-TM GnRHR2 isoform 
(containing TM domains 1–4 and 6–7) reassociated, they would 
form a 6-TM isoform. However, it is unclear if a 6-TM receptor 
would be functional (82).
The final theory is that GnRHR2 fragments are successfully 
produced and modulate GnRHR1 activity (82). This hypothesis 
is seemingly supported by the work of Pawson et al. (93) who 
demonstrated that a GnRHR2 protein fragment (termed the 
GnRHR2 reliquium) inhibits post-translational GnRHR1 protein 
TABLe 5 | Continued
signifies that GnRHR1 has adopted a dual role for the actions 
of GnRH1 and GnRH2 through alternative ligand conforma-
tions and downstream signaling events. In species that produce 
both GnRH2 and its receptor, however, this system was likely 
critical to survival to have avoided gene inactivation throughout 
evolution.
Does the Human Produce the GnRHR2?
When GnRHR2 was first discovered in mammals, GnRHR2-
specific immunostaining was detected in the human brain (29), 
implying that humans produce a full-length GnRHR2. However, 
it was later discovered that coding errors likely interrupt suc-
cessful translation of human GnRHR2 mRNA (21). Indeed, Neill 
et al. (82) reported the inability to identify translatable GnRHR2 
transcripts that would yield a full-length receptor in humans, at 
least via conventional mechanisms. Recall, the human GnRHR2 
gene contains a frameshift mutation in exon 1 and a premature 
stop codon in exon 2 (76, 82). Yet, the gene remains transcrip-
tionally active and produces transcript variants due to alterna-
tive splicing, suggesting functionality as most pseudogenes are 
promoterless (76). These conflicting results have been the subject 
of much research and debate.
Despite the apparent gene coding errors, there is evidence for 
functionality of the GnRHR2 in humans (82). For example, use 
of a GnRHR1 antagonist mitigated the effects of GnRH1, but not 
GnRH2, in human decidual stromal (83) and trophoblast (84) 
cells. GnRH2, and not GnRH1, effectively suppressed prolifera-
tion of SK-OV-3 cells containing only GnRHR2 mRNA (51). In 
FiGURe 3 | Activity of the porcine GnRHR1 and GnRHR2 gene promoters within different mammalian cell lines. Cells were transiently transfected with either the 
porcine GnRHR1 (white) or GnRHR2 (black) gene promoter in a luciferase reporter vector and expressed as fold activity over the promoterless control. Abbreviations: 
HELA, human cervical cancer; DON, Chinese hamster lung; MSC-1, mouse Sertoli cell; STO, mouse embryonic fibroblast; JAR, human placenta; MA-10, mouse 
Leydig cell; MCF7, human breast cancer; IPEC-J2, piglet intestinal epithelium; C2C12, mouse muscle myoblast; 3T3-L1, mouse adipocyte fibroblast; COS-7, green 
monkey kidney; PK15, porcine kidney; PGC-2, porcine granulosa cell; ST, swine testis; and αT3-1, murine gonadotrope. An asterisk indicates Least Squares Means 
that are significantly greater than the promoterless control (P < 0.05). Reprinted from Brauer et al. (75) with permission from Elsevier.
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abundance via interactions with GnRHR1 inside the nucleus, 
endoplasmic reticulum, and/or Golgi apparatus (93). This 
fragment spans the cytoplasmic end of the 5-TM domain to 
the carboxyl terminus of the full-length receptor and would be 
produced by the aforementioned alternative start site (GUG) 
downstream of the premature stop codon (93). Interestingly, 
others have reported that GnRHR1 fragments with similar 
domains (TM6–7) suppress GnRH-mediated signaling when 
coexpressed with the full-length GnRHR1 (92). This theory is 
supported by early work revealing GnRHR2 immunostaining in 
human tissues with an antibody (ZGRH-II-5) directed against 
ECL3 (29), which is retained in the GnRHR2 reliquium (93). 
Likewise, the ovine GnRHR2 gene may produce a GnRHR2 
reliquium as well, given that ZGRH-II-5 antiserum also revealed 
GnRHR2 immunostaining in the sheep brain (93). In contrast, a 
different antibody directed against ECL2 (absent in the GnRHR2 
reliquium) failed to indicate GnRHR2 immunostaining in sheep 
(93). Notably, mRNA that encodes for the GnRHR2 reliquium 
has been successfully identified in many human organs and cell 
lines, suggesting that this protein fragment may be physiologically 
relevant (76). In addition, when the full-length cDNA sequence 
for human GnRHR2 (including frame shift and premature stop 
codon) is transiently transfected into COS cells, expression of 
GnRHR1 is enhanced (18). Thus, it is plausible that a functional 
(albeit unconventional) GnRHR2 is produced in humans. To 
date, however, the controversy remains unresolved and actions 
of GnRH2 in humans are predominantly ascribed to GnRHR1 
signaling.
Characterization of the Mammalian 
GnRHR2 Gene Promoter
While transcriptional regulation of the GnRHR1 gene has been 
evaluated in mice (94), rats (95), humans (96), sheep (97), 
and pigs (98), much less is known regarding the regulation of 
GnRHR2 gene expression. The GnRHR2 gene is transcriptionally 
active in several mammals, including humans, sheep, monkeys, 
marmosets, musk shrews, and pigs (11, 32, 46, 81, 82, 99). 
However, the regulatory elements governing the expression of 
this gene have only been studied in the marmoset and pig (75, 99). 
Utilizing luciferase reporter constructs containing either the 
GnRHR1 or GnRHR2 pig promoter in transient transfection 
assays with cell lines from several tissues, the GnRHR2 promoter 
was active in all cell types examined, whereas activity of the 
GnRHR1 promoter only exceeded the promoterless control in 
gonadotrope-derived αT3-1 cells [Figure 3; (75)]. Initial studies 
in immortalized swine testis (ST) cells revealed that activity of 
the porcine GnRHR2 promoter was partially conferred by nuclear 
factor-κB, specificity protein 1 and 3 (SP1/3), and overlapping 
early growth response 1/SP1/3 (EGR1/SP1/3)-binding sites (75). 
The EGR1 and SP1/3-binding sites are located in a region of the 
5′ UTR that is highly conserved compared with the marmoset 
GnRHR2 promoter and previously shown to enhance promoter 
TABLe 6 | Structural and functional characteristics of GnRHR1 and GnRHR2 in 
mammals.a
Characteristic GnRHR2 GnRHR1 Reference
Structure
Number of amino acids 377–380 327–328 (16, 74, 104)
5-transmembrane isoform + − (80)
C-terminal tail + − (16, 74, 104)
Amino acid conferring receptor 
activation in TM2 and TM7
Asp/Asp Asn/Asp (74, 105)
Amino acids conferring ligand 
selectivity in ECL3
Val–Pro–
Pro–Ser
Leu–Ser–Asp/
Glu–Pro
(106)
Relative-binding affinities of native peptidesb
GnRH1 1 15 (16)
GnRH2 24 1 (16)
Relative activities of native peptidesc
GnRH1 1 12 (16, 80)
GnRH2 90–440 1 (11, 16, 80)
Relative activities of GnRHR agonistsc
[d-Ala6] GnRH1 1 309 (80)
[d-Ala6] GnRH2 4 1 (104)
Buserilin 1 548 (80)
Triptorelin 1 395 (80)
Relative activities of GnRHR antagonistsc
Cetrorelix (SB-75) 1 >5,050 (80)
Trptorelix-1 1,660 1 (104)
Antide 1 >9,523 (80)
Antagonist 135-18 Full agonist Full antagonist (16)
Coupling and signaling
Gαq/11 + + (16)
Inositol phosphate (IP) + +
Ca2+ + + (16, 50)
Protein kinase C + + (16)
ERK 1/2 + (sustained) + (transient) (16)
p38 MAPK + − (16)
c-Jun N-terminal kinase − − (16)
Mammalian homolog r-Src of 
Rous sarcoma virus (c-Src)
− + (16)
Receptor internalization
Rapid desensitization + − (16)
Internalization rate Rapid Slow (16)
β-Arrestin-dependentd − − (102, 103, 107)
Dynamin dependente + −/+ (103, 107)
Clathrin mediated + + (103, 107)
aAdapted from Millar (16) and Cheng and Leung (108).
bRelative fold increase in affinity compared with the non-cognate ligand.
cRelative fold increase in activity compared with the non-cognate ligand or analog.
dInternalization of GnRHR2 can be mediated via β-arrestin but it is not required.
eGnRHR1 internalization is dependent on dynamin in the rat but not human.
Abbreviations: TM, transmembrane; ECL, extracellular loop; ERK 1/2, extracellular 
signal-regulated kinase 1 and 2; MAPK, mitogen-activated protein kinase.
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activity (99). Given the ubiquitous expression of GnRHR2, it 
was not surprising that a transcription factor such as SP1, also 
considered to be widely produced, would be involved in regula-
tion. This contrasts greatly from the three steroidogenic factor 
1-binding elements required for basal expression of the porcine 
GnRHR1 gene in the gonadotrope-derived αT3-1 cell line (98). 
So, in accord with divergent expression patterns of the GnRHR1 
and GnRHR2 genes, their transcription is differentially regulated 
as well.
The GnRHR2 Gene is Ubiquitously 
expressed in Mammals
Similar to GnRH2, the GnRHR2 gene is widely expressed through-
out the body (11, 29). Within the brain, the GnRHR2 was found 
in the forebrain, midbrain, and hindbrain (16). Expression was 
pronounced in areas that regulate sexual behavior, such as the 
putamen, occipital lobe, cerebellum, and caudate nucleus, but 
reduced within the anterior pituitary gland (29). In addition, 
GnRHR2 mRNA was also found in peripheral tissues including the 
heart, stomach, intestine, kidney, spleen, skeletal muscle, thymus, 
lung, liver, pancreas, adrenal, thyroid, placenta, uterus, ovary, 
breast, seminal vesicles, epididymis, prostate, and testis [Table 3; 
(11, 29)]. Relative to GnRHR2 mRNA amounts in the pituitary, 
expression levels were lowest in the marmoset bladder and highest 
in the testis (29). Likewise, van Biljon et al. (46) detected strong 
GnRHR2 signal in the human testis via in situ hybridization and 
our laboratory reported abundant GnRHR2 protein levels in 
the testis compared with the anterior pituitary gland of the pig 
(35). The receptor has been found in reproductive cancer cell lines 
derived from the prostate, cervix, endometrium and ovary, as well 
as cell lines produced from other organ systems (e.g., respiratory, 
digestive, mammary, immune, and urinary; Table 4). GnRHR2 
was also identified by our laboratory in cell lines derived from 
porcine intestine and testis [Table 4; (48)]. Our group has also 
detected GnRHR2 mRNA in various porcine tissues (e.g., testis, 
anterior pituitary, spleen, liver, large intestine, small intestine, and 
stomach) using conventional PCR (48).
The Structure of GnRHR2
The full-length porcine GnRHR2 is 377 amino acids (NCBI acces-
sion number AAS68622.1) and has 42% homology to GnRHR1, 
which is 328 amino acids in length (Table 6; Figures 4A,B; NCBI 
accession number NP_999438.1). Like GnRHR1, the GnRHR2 is 
a member of the rhodopsin superfamily of GPCRs containing an 
extracellular N-terminus as well as seven TM α-helical domains 
connected via three ECLs and three ICLs [Figures 4A,B; (74)]. 
Differences in amino acid number within the domains of 
GnRHR1 and GnRHR2 are depicted in Figure  4D. Strikingly, 
GnRHR2 maintains a 52 amino acid C-terminal tail that is 
uniquely absent in GnRHR1 but similar to non-mammalian 
GnRHRs [Figures  4A,B; (74)]. Cytoplasmic tails are common 
among GPCRs and promote rapid receptor internalization and 
desensitization (100, 101). For example, the monkey GnRHR2 
fully desensitized to GnRH2 treatment after 60  min whereas 
the tail-less human GnRHR1 failed to desensitize to a GnRHR1 
agonist (Triptorelin) during the entire sampling period [90 min; 
(80)]. The cytoplasmic tail contributes to internalization differ-
ences between GnRHR1 and GnRHR2 as well. GnRHR1 is inter-
nalized without interacting with β-arrestin, whereas GnRHR2 
can utilize β-arrestin for internalization (102), although it is 
not absolutely required (Table 6) (103). The phosphorylation of 
serine residues 338 and 339 in the C-terminus by GPCR kinases 
is critical for β-arrestin-independent internalization of GnRHR2 
(103), whereas other regions within the C-terminal tail or ICL3 
FiGURe 4 | Structural comparison of GnRHRs in the pig. (A) GnRHR1 (B) GnRHR2 and (C) predicted 5-transmembrane (TM) GnRHR2 in the pig. GnRHR1 and 
GnRHR2 are both 7-TM G-protein coupled receptors; however, GnRHR1 lacks a C-terminal tail present in GnRHR2. The 5-TM GnRHR2 isoform lacks TM domains 1 
and 2 due to alternative splicing in exon 1 of the GnRHR2 gene, resulting in coupling of a truncated extracellular N-terminus directly to TM3. Glycosylation sites are 
represented by branched structures (Y) and the darkened residues in the GnRHR2 isoforms represent predicted sites of phosphorylation for internalization based on 
the work of Madziva et al. (102) and Ronacher et al. (103). Structures are predicted according to NCBI database records (GnRHR1, accession number 
NP_999438.1; GnRHR2, accession number AAS68622.1; 5-TM GnRHR2, accession number AAS68623.1). Adapted from Neill (80) and Neill et al. (82) with 
permission from Oxford University Press and Elsevier. (D) Comparison of residue number within each domain of GnRHR1, GnRHR2, and the predicted 5-TM 
GnRHR2 in the pig. Abbreviations: NT, extracellular N-terminus; TM, transmembrane; ICL, intracellular loop; ECL, extracellular loop; CT, C-terminal tail.
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are sufficient for β-arrestin-dependent internalization (102). 
Therefore, two distinct pathways coordinate internalization of 
GnRHR2 (103). In addition, GnRHR2 internalization is depend-
ent upon dynamin and likely mediated by both clathrin-coated 
pits and caveolae (103).
Other notable differences between the structure of GnRHR1 
and GnRHR2 include alterations in residues that are highly 
conserved among GPCRs. GnRHR2 has an Asp/Asp micro-
domain in TM2 and 7, which is prevalent among GPCRs (74), 
whereas the GnRHR1 has a distinct Asn/Asp domain (Table 6). 
This region is thought to be important for receptor configura-
tion and activation (105). Likewise, GnRHR2 has a divergent 
ligand-binding site (Val–Pro–Pro–Ser) within ECL3 compared 
with GnRHR1 (Leu–Ser–Asp/Glu–Pro; Table 6). This sequence 
probably determines the selectivity of GnRHR2 for GnRH2, 
as all other known ligand-binding sites are conserved between 
GnRHR1 and GnRHR2 (106). GnRHR2 and GnRHR1 also differ 
in the charge distributions of their extracellular domains, which 
may affect ligand binding (30).
A 5-Transmembrane GnRHR2 isoform
A 5-TM GnRHR2 isoform has been identified in pigs [Figure 4C; 
(109)]. Transcripts from this isoform are produced via alternative 
splicing in exon 1 and a different start codon. Therefore, TM1 
and 2 are absent and the truncated extracellular N-terminus, 
comprised primarily of residues from ECL1, couples directly to 
TM3 [Figures  4C,D; (82)]. Transcripts for the 5-TM isoform 
were originally isolated from porcine pituitaries (109) but we have 
also found the 5-TM GnRHR2 transcript in various tissues of the 
boar (e.g., testis, spleen, liver, large intestine, small intestine, and 
stomach) via conventional RT-PCR (48). The 5-TM transcript 
possesses all the characteristics of a translatable protein (109, 110) 
and would yield a 286 amino acid receptor (Figures  4C,D). 
Functionality of the 5-TM GnRHR2 has not been characterized 
thus far, but there is precedence for biologically active 5-TM 
GPCRs (111–114). As noted previously, the human may also 
produce a 5-TM GnRHR2 transcript; however, it retains an in-
frame premature stop codon (82).
THe iNTeRACTiON BeTweeN GnRH2 
AND GnRHR2
Functionality and Ligand Selectivity  
of GnRHR2
Receptor binding (29) and inositol phosphate (IP) accumulation 
(11, 29) assays established the selectivity of GnRH2 for GnRHR2. 
The binding affinity of GnRH2 for GnRHR2 is 24-fold greater 
than for GnRHR1 [Table  6; (29)]. When COS-1 cells overex-
pressing porcine GnRHR2 cDNA were treated with GnRH2 or 
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GnRH1, production of IP was stimulated with an EC50 of 0.5 nM 
for GnRH2 and 220 nM for GnRH1 (109). Conversely, the EC50 
for GnRH2 binding the human GnRHR1 was 7.41 nM compared 
with 0.63 nM for GnRH1. The African green monkey (11) and 
marmoset GnRHR2 (29) were found to be functional and selec-
tive for GnRH2 as well. Thus, GnRH2 is 100- to 400-fold more 
active at the GnRHR2 than is GnRH1. In contrast, GnRH1 is only 
approximately 10-fold more active at GnRHR1 than is GnRH2 
(Table 6).
Since GnRH1 and GnRH2 activate alternative GnRHRs, it 
became prudent to assess whether GnRH analogs are actually 
specific to their cognate receptors. However, it appears that 
GnRH1 and GnRH2 analogs, including GnRHR1 superagonists 
(Triptorelin and Buserilin), remain specific (Table 6) (80). At the 
GnRHR2, the native peptide (GnRH2) had an EC50 of 0.58 nM 
compared with 7.5 and 48  nM for Triptorelin and Buserilin, 
respectively. Therefore, GnRH2 is about 13- to 83-fold more 
potent at the GnRHR2 than are GnRHR1 superagonists (80). 
Non-native GnRH peptides (e.g., GnRH3) were considerably 
less potent (0.02%) than GnRH2 at eliciting IP production (80). 
Receptor specificity was also verified for GnRHR antagonists. 
Trptorelix-1 was identified as a GnRHR2-specific antagonist (104, 
115), whereas Cetrorelix (also known as SB-75) and Antide are 
reported to be selective for GnRHR1 (80). For example, Antide 
mitigates both GnRH1- and GnRH2-induced IP production 
in cells overexpressing GnRHR1 but failed to ablate GnRH2-
induced IP production in COS-7 cells overexpressing GnRHR2 
(69). At elevated concentrations, however, Cetrorelix (SB-75) 
can non-specifically bind the GnRHR2 (50, 115). In addition, 
an established GnRHR1 antagonist (antagonist 135–18) was 
found to have agonistic properties at GnRHR2 (29). These data 
demonstrate the functionality and selectivity of the mammalian 
GnRHR2, but also indicate that both GnRHs can bind both 
mammalian receptors. However, GnRHR2 is highly selective for 
GnRH2, whereas GnRHR1 binds both ligands relatively well (16). 
Therefore, early studies examining the function of GnRH2 may 
be limited given that receptor binding was not addressed, and 
the actions of GnRH2 may have been inappropriately ascribed 
to GnRH1 (82).
Cell Signaling of GnRHR2
Like GnRHR1, GnRHR2 couples to Gαq/11 to initiate the produc-
tion of IP, calcium mobilization, and the activation of protein 
kinase C (PKC; Table 6) (16, 84, 116). After the activation of PKC, 
however, GnRH1 and GnRH2 differentially stimulate mitogen-
activated protein kinases (MAPKs) (29). GnRH1 transiently 
activated extracellular signal-regulated kinases 1/2 (ERK 1/2) 
and the proto-oncogene tyrosine-protein kinase, Src (c-Src) in 
COS-7 cells overexpressing GnRHR1 [Table 6; (29)]. Conversely, 
GnRH2 did not activate c-Src; instead, the interaction between 
GnRH2 and GnRHR2 activated ERK 1/2 in a prolonged manner 
as well as p38 MAPK in COS-7 cells overexpressing GnRHR2 
(Table 6) (16, 29). Neither GnRH1 nor GnRH2 activated c-Jun 
N-terminal kinase (JNK) via their cognate receptors [Table  6; 
(29)]. Therefore, GnRHR1 and GnRHR2 exhibit differential 
signaling upon binding to their respective ligands. Moreover, 
activation of GnRHR1 by GnRH2 initiates different signaling 
pathways than GnRH1 (18). The seminal research uncovering 
the divergent signaling of GnRHR2 was conducted in transiently 
transfected cell lines (COS-7) by Millar et al. (29). More recent 
work utilizing immortalized human cancer cell lines has further 
explored GnRH2-induced signaling (50, 117–120). Although it 
is often unclear which receptor (GnRHR1 or GnRHR2) mediates 
the signal, because the presence of the GnRHR2 in humans is 
controversial (82). Another limitation is the use of cancer cells, 
which are inherently abnormal. Thus, there is a gap in our knowl-
edge regarding the signaling cascades of GnRHR2 under normal 
physiologic conditions.
DiveRGeNT PHYSiOLOGiCAL eFFeCTS 
OF GnRH2 ACTivATiNG GnRHR1 AND 
GnRHR2
Gonadotropin Secretion
It was originally hypothesized that GnRH2 might function simi-
larly to GnRH1 and elicit gonadotropin release from the anterior 
pituitary gland (12) or could be the much sought after FSH-
releasing factor (16, 121–123). In support of these hypotheses, 
GnRH2 is present within regions of the brain (e.g., pre-optic and 
medio-basal hypothalamic areas) associated with the regulation 
of gonadotropin secretion (16). However, GnRH2 production 
in hypothalamic regions is scarce (33) and GnRH2 does not 
coexpress with GnRH1 in the hypothalamus (124). In contrast, 
GnRH2 is more highly abundant in other regions of the brain, 
such as the midbrain (28, 36, 37). Immunopositive GnRHR2 
was detected on 69% of mammalian gonadotrope cells (29) but 
GnRH2 has never been isolated from hypothalamic portal blood 
(69, 125). Our laboratory detected immunoreactive GnRH2 in 
the hypothalamus of pigs, but abundance was low compared 
with the testis (34, 35). Millar et  al. (29) identified GnRHR2 
in the pituitary of the marmoset, although it was expressed at 
similar levels in numerous tissues unrelated to reproduction. 
It is now well established that GnRH2 and GnRHR2 are more 
highly expressed in peripheral tissues than the hypothalamus and 
anterior pituitary gland, respectively (20, 29, 33, 35), suggesting 
little role in gonadotropin secretion.
Upon its discovery, Miyamoto et  al. (12) demonstrated that 
GnRH2 was less effective than GnRH1 at eliciting release of LH 
(68% less) and FSH (59% less) from pituitary cell cultures derived 
from rats. Other investigators confirmed these results in the rat 
and sheep through in vitro studies (125–127). GnRH2 was 92% 
less effective than GnRH1 at stimulating gonadotropin secretion 
from primary cultures of ovine pituitary cells (126). In vivo, a 
bolus (10 µg) of GnRH2-stimulated LH and FSH release in rams, 
although less robustly (40-fold) than GnRH1. There was a mod-
est preference (2-fold) for FSH over LH secretion in response to 
treatment with GnRH2 (29). In the rat (121) and rhesus macaque 
(128), however, GnRH2 did not preferentially stimulate FSH 
release compared with GnRH1.
The effects of GnRH2 on gonadotropin secretion in rats and 
sheep are likely mediated through the GnRHR1, because both 
species lack GnRHR2 (21) and GnRHR1 can be activated by 
GnRH2, although with 10-fold less activity than GnRH1 (29). 
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Indeed, a GnRHR1-specific antagonist completely blocked both 
chronic and acute GnRH2-stimulated secretion of gonadotropins 
in sheep (69) as well as in pituitary cell cultures that were derived 
from rats (127). These data provide strong evidence that GnRH2 
is a weak stimulator of gonadotropin secretion in mammals via 
interaction with GnRHR1, although it remains plausible that this 
interaction, albeit minimal, may still be physiologically relevant 
(80). For example, it has been suggested that GnRH2 primes 
activity and/or production of GnRHR1. However, cotreatment 
of monkey pituitary cells (125, 128) and rams (69) with GnRH2 
and GnRH1 did not enhance LH or FSH secretion above GnRH1 
treatment alone. Alternatively, Urbanski (129) proposed that 
GnRH2 activates GnRHR1 to mediate the preovulatory LH surge. 
However, this hypothesis has not yet been evaluated in vivo.
The effect of GnRH2 on secretion of LH and FSH in species 
that produce a functional GnRHR2 has also been examined. 
Treating musk shrews with GnRH2-stimulated ovulation, with 
10-fold less potency than GnRH1, but this effect could be blocked 
with a GnRHR1 antagonist (33). Treating rhesus macaques with 
GnRH2 elicited increased secretion of gonadotropins in  vivo 
during the follicular and luteal phase of the menstrual cycle, 
but the response was not compared with GnRH1 (37). Others 
showed that a high dose (1  µg/kg of body weight) of GnRH1 
and GnRH2 were equipotent at stimulating release of LH and 
FSH in the female rhesus macaque (128). However, in cultures 
of pituitary cells derived from male rhesus macaques, GnRH2 
was a less effective stimulator of gonadotropin secretion than 
GnRH1 (125). GnRH2 stimulated secretion of LH with an EC50 
of 0.37 nM (compared with 0.10 nM for GnRH1) and FSH with 
an EC50 of 0.59 nM (versus 0.10 nM for GnRH1) (125). Receptor 
antagonism was used to clarify if GnRHR1 or GnRHR2 mediated 
these effects. Interestingly, GnRH2-induced gonadotropin secre-
tion was completely blocked by treatment with Antide (125, 128), 
a GnRHR1-specific antagonist that has minimal activity (EC50 of 
10,000 nM) at the GnRHR2 (80). Thus, the stimulatory effects of 
GnRH2 on gonadotropin secretion were attributed to its interac-
tion with GnRHR1.
Similar results were observed in the pig; Cetrorelix (GnRHR1 
antagonist) mitigated GnRH2-induced LH and FSH secretion 
from porcine gonadotrope cell cultures (109). Data from our 
laboratory support these results. Treatment of boars with [d-Ala6] 
GnRH2 weakly stimulated secretion of LH compared with 
[d-Ala6] GnRH1 (35). In addition, treatment of males with a 
GnRHR2-specific antagonist (Trptorelix-1) failed to suppress LH 
secretion (35). Likewise, immunization of boars against GnRH2 
did not affect gonadotropin secretion compared with control 
males (130). Finally, LH secretion was unaffected in transgenic 
swine with ubiquitous knockdown of GnRHR2 (53). Collectively, 
these data demonstrate that only high doses of GnRH2 can elicit 
weak gonadotropin release via the GnRHR1. Therefore, GnRH2 
and its receptor do not appear to be physiological stimulators of 
gonadotropin secretion in mammals.
Reproductive Behavior and energy 
Balance
Given the neuroanatomical location of GnRH2 (e.g., midbrain 
and limbic structures), investigators hypothesized that it may 
be important in sexual behavior (14, 29, 131). The first evidence 
demonstrating a role for GnRH2 in female reproductive behavior 
occurred when GnRH2, but not GnRH1, infusions into the brain 
of female sparrows increased receptivity to songs of male spar-
rows (132). In mammals, the effects of GnRH2 on sexual behavior 
may be dependent on metabolic state. When feed was restricted 
by 60%, female musk shrews displayed fewer sexual behaviors (31) 
and had reduced GnRH2 mRNA expression (midbrain GnRH2 
cells) and protein abundance (ventromedial nucleus, medial 
habenula, GnRH2 cells, and midbrain central gray) compared 
with ad  libitum fed animals (133). Sexual behaviors as well as 
GnRH2 mRNA expression (midbrain) and protein levels in some 
regions (ventromedial nucleus and medial habenula) returned to 
normal after only 90 min of ad libitum feeding after restriction 
(133). The lordosis response in mice during nutrient restriction 
was enhanced by GnRH2, but not GnRH1 (134); no effect of 
GnRH2 on lordosis was observed when female mice were fed 
ad libitum. Mice lack GnRH2 and GnRHR2 (30), therefore the 
biological significance of these results is unclear. In male musk 
shrews, GnRH2 abundance was examined in all regions of the 
midbrain prior to and after feed restriction. Unlike females, 
GnRH2 abundance and sexual behaviors were not affected by 
feed restriction in male musk shrews. This is potentially due to 
sexually dimorphic expression patterns of GnRH2 between male 
and female musk shrews or the level of feed restriction (133, 135).
The enhancement of sexual behaviors in female musk shrews 
treated with GnRH2 during feed restriction were not attenuated 
by the addition of a GnRHR1 antagonist (Antide), suggesting the 
effect of GnRH2 on sexual behavior is mediated via the GnRHR2 
(32). Similarly, reproductive behaviors of female musk shrews 
during food restriction were rescued by treatment with antago-
nist 135–18 (32), which simultaneously acts as an antagonist 
of GnRHR1 and an agonist of GnRHR2 (29). This agrees with 
results in female marmoset monkeys showing that GnRH2 and 
antagonist 135–18, but not GnRH1, increased proceptive (sexual 
solicitation) behaviors (136). In contrast, other studies showed 
that high doses (25 µg) of GnRH1 do elicit sexual proceptivity of 
female marmosets (137), but these effects are likely mediated by 
GnRHR2 (136).
The interaction between metabolic state and the effects of 
GnRH2 on sexual behavior may be related to the potential effects 
of GnRH2 on the mechanism of food intake. Intracerebroven-
tricular infusions of GnRH2 reduced feed intake (33%) in female 
musk shrews that were underfed (138). A similar reduction 
(28%) in food intake of musk shrews was also apparent with 
GnRH2 treatment during ad libitum feeding (138). The ability of 
GnRH2 to reduce food intake was acute, beginning 90 min after 
GnRH2 infusion and persisting for 3 h, regardless of nutritional 
plane (138). The effect of GnRH2 on food intake is probably medi-
ated through the GnRHR2 as treatment with Antide (GnRHR1 
antagonist) did not prevent a GnRH2-induced reduction in feed 
intake (32).
The results of these studies demonstrate that GnRH2 influ-
ences female reproductive behavior through the GnRHR2, not 
GnRHR1. GnRH2 may be acting as a permissive neuropeptide 
that links reproductive behavior with nutritional status in some 
species (32, 136). If energy balance is low, GnRH2 production is 
FiGURe 5 | Both GnRH2 and GnRHR2 are abundantly produced within the porcine testis. (A) GnRH2 levels were determined via ELISA of homogenates from the 
hypothalamus, anterior pituitary gland, and testis of males (n = 6). a,bBars with alternate letters differ (P < 0.0001). (B) Representative western blot of anterior 
pituitary gland and testicular tissue from boars (n = 5) using an antibody directed against GnRHR2 (upper panel). Immunoblot quantification revealed a difference in 
GnRHR2 protein levels between tissue types (*P < 0.0001; lower panel). (C) GnRH2 is primarily localized to the tubular compartment of the porcine testis. 
Representative immunofluorescence image (400×; merge of fluorescence and transmitted light) of porcine testes (n = 5) using an antibody directed against GnRH2 
(red). (D) GnRHR2 localizes to both the tubular and interstitial compartments of the porcine testis. Representative immunohistochemistry image (400×) of porcine 
testes (n = 7) using an antibody directed against GnRHR2 (purple). Reprinted from Desaulniers et al. (35) with permission from Oxford University Press.
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decreased, inhibiting reproductive behaviors and increasing feed 
intake. If energy is abundant, increased GnRH2 expression will 
promote mating behaviors (32).
Testicular Function
For 35  years, evidence has been accumulating that GnRH1 
and GnRHR1 have extrapituitary functions. Both GnRH1 and 
GnRHR1 are expressed within the testes of some mammals 
(e.g., humans, rats, and mice) (139–144) and their interaction 
directly elicits testosterone secretion from Leydig cells (145–148). 
The contribution of GnRH1 and its receptor to localized control 
of gonadal function is not well understood and therefore often 
overlooked (149). Localized regulation of the gonads by GnRHs 
may have existed early in evolution to control reproduction before 
the formation of an organized pituitary gland (7). For instance, 
GnRH peptides control reproductive function of invertebrates 
(e.g., mollusks, echinoderms, and prochordates) that lack an 
anterior pituitary gland (150–152). Ciona intestinalis synthesizes 
GnRH1 and GnRH2 directly within its gonads and treating 
gonadal cultures with GnRH1 and GnRH2 stimulates secretion of 
sex steroids (153). Moreover, seven novel tunicate GnRHs stimu-
lated the release of gametes in C. intestinalis, indicative of direct 
action on the gonads (152). Local control of gonadal function 
may have been retained in mammals for a specific purpose not 
met by the gonadotropins. McGuire and Bentley (149) proposed 
that function might be a rapid, transient responsiveness to envi-
ronmental stimuli.
Of the 31 organs examined in the marmoset monkey, GnRHR2 
transcript levels were most abundant in the testis (29). In fact, sev-
eral laboratories have now reported the presence of GnRH2 and/
or its receptor within mammalian testes (11, 20, 29, 35, 46, 154), 
suggesting an autocrine/paracrine role in testicular function. 
Abundance of GnRH2 in the testis of the pig was 7-fold greater 
than levels within the anterior pituitary gland or hypothalamus 
(Figure  5A) (35). This corresponded to 6-fold more GnRHR2 
protein in the testis than in the anterior pituitary gland 
FiGURe 6 | Subcellular localization of the GnRHR2 in a swine testis (ST)-derived cell line. Immunocytochemistry was performed on ST cells (CRL-1746; American 
Type Culture Collection, Rockville, MD, USA) with an antibody directed against GnRHR2 (1:100–1:200; sc-162889; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and labeled with an Alexa Fluor 488 secondary antibody (green); nuclei were stained with DAPI (blue). The experiment was replicated three times. Two 
representative confocal microscopy images are shown. Note the plasma membrane and perinuclear staining (arrows). The scale bar represents 10 µm. Adapted 
from Cederberg et al. (48).
17
Desaulniers et al. GnRH2 and GnRHR2 in Mammals
Frontiers in Endocrinology | www.frontiersin.org December 2017 | Volume 8 | Article 269
(Figure 5B). We also observed the most intense GnRH2 immu-
nostaining within the seminiferous tubules of the boar, primarily 
localizing to germ and Sertoli cells (Figure  5C) (35), although 
some signal was present within the interstitium. Likewise, we have 
detected immunoreactive GnRHR2 on germ and Sertoli cells as 
well as the plasma membrane of porcine Leydig cells (Figure 5D). 
Subcellular localization of GnRHR2 in immortalized ST-derived 
cells, recently shown to exhibit Sertoli cell-like properties (155), 
revealed plasma membrane as well as perinuclear immunostain-
ing (Figure  6) (48). These data establish that GnRH2 and its 
receptor are abundantly produced in the porcine testis, indicating 
an important autocrine/paracrine role in testis biology.
The first association of GnRH2 with testicular function was 
reported in humans. Although the levels of GnRHR2 mRNA were 
not evaluated, testicular GnRH1, GnRH2, and GnRHR1 transcript 
abundance was increased in infertile (azoospermic) men, cor-
responding with elevated intra-testicular testosterone levels and 
increased expression of genes encoding steroidogenic enzymes 
(CYP11A1 and HSD3B) (154). Notably, GnRH1 and GnRH2 
mRNA levels were positively correlated with expression of HSD3B, 
intra-testicular testosterone levels, and concentrations of FSH in 
serum, indicating that the testicular GnRH system helps regulate 
spermatogenesis and steroidogenesis in humans (154). Consistent 
with this, GnRHR2 transcripts have been detected in post-meiotic 
germ cells and human sperm (46). Our laboratory has immunolo-
calized GnRHR2 to ejaculated porcine spermatozoa, implying a 
role for GnRH2 in sperm function of boars (34, 45). In contrast, 
it was concluded that GnRH2 did not impact spermatogenesis in 
mice (156); however, mice lack both GnRH2 and its receptor (21), 
which limits the interpretation of these results.
Based upon the aforementioned discovery of GnRHR2 on 
porcine Leydig cells (35), our laboratory became interested 
in whether GnRH2 and its receptor are autocrine/paracrine 
regulators of steroidogenesis in the pig. Previous research has 
indirectly revealed a role for GnRH2 and its receptor within 
the testes of mature swine. For example, testosterone secretion 
was reduced in males immunized against GnRH2, but concen-
trations of LH in serum remained unchanged (130). Primary 
cultures of Leydig cells from boars immunized against GnRH2 
demonstrated impaired secretion of testosterone basally and 
when stimulated with LH (130). In a different study, treatment 
of males with a GnRHR1 antagonist (SB-75; Cetrorelix) blunted 
hCG-induced secretion of testosterone (157). In a subsequent 
trial, release of testosterone in boars was continuously reduced 
during chronic administration of SB-75, yet secretion of LH was 
only transiently suppressed (158). In addition, SB-75 attenuated 
hCG-stimulated secretion of testosterone from porcine testicular 
explants (158). These data imply that a testicular GnRHR was 
directly regulating steroidogenesis locally within the swine testis. 
Given that GnRHR1 is not expressed within the porcine testis 
(158), the results of these studies may be ascribed to GnRHR2. 
Therefore, we hypothesized that GnRH2, produced locally in the 
testis, binds to the GnRHR2 on porcine Leydig cells to stimulate 
LH-independent secretion of testosterone.
To test this hypothesis, we treated porcine testicular explants 
with hCG in the presence or absence of GnRH2. Secretion of 
testosterone was significantly stimulated after treatment with 
GnRH2 or hCG but there was no synergistic effect of treating 
with hCG and GnRH2 (35). These results established that GnRH2 
was a stimulator of acute testosterone secretion ex vivo. We next 
tested the effect of GnRH2 in vivo. White crossbred boars were 
fit with indwelling jugular cannulae to perform serial bleeding 
trials following treatment with GnRH analogs. GnRH2 infu-
sion robustly elicited testosterone secretion, similar to GnRH1 
treatment, despite minimal LH secretion when compared 
with GnRH1-stimulated males [Figure  7; (35)]. Furthermore, 
GnRH2-induced secretion of testosterone was blunted by pre-
treatment with the GnRHR1 antagonist, SB-75 (35), which can 
FiGURe 7 | GnRH2 stimulates secretion of testosterone similar to GnRH1 
despite reduced luteinizing hormone (LH) release in mature male pigs. 
Plasma concentrations of LH (A) and testosterone (B) after intravenous 
administration of [d-ala6] GnRH1 (solid line; n = 8) or [d-ala6] GnRH2 (dotted 
line; n = 6) to cannulated adult males. After pretreatment sampling, 
treatments were administered (arrow; 0 min) and blood was serially collected. 
Data are presented as the Least Squares Means (±SEM). For LH, Treatment, 
P < 0.001; Time, P < 0.0001; Treatment × Time, P < 0.03. For testosterone, 
Treatment, P = 0.1929; Time, P < 0.002; Treatment × Time, P = 0.7190. 
*Within treatment, concentrations differ from pre-injection levels (P < 0.05). 
GnRH1 differences are indicated above error bars and GnRH2 differences  
are labeled below error bars. Reprinted from Desaulniers et al. (35) with 
permission from Oxford University Press.
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antagonize GnRHR2 (50, 115). We hypothesize that SB-75 
reduced GnRH2-induced testosterone secretion by antagonizing 
GnRHR2 directly in the testis because the secretory pattern of 
LH was unaffected compared to trials where only GnRH2 treat-
ments were administered (35). Finally, intratesticular injections 
of either GnRH1 or GnRH2 stimulated secretion of testosterone 
compared with saline-treated controls; however, GnRH2 did 
so without eliciting the release of LH, unlike GnRH1 (159). 
Together, these data support our hypothesis that GnRH2 is 
stimulating testosterone production directly at the testis in the 
absence of the classical androgen regulator, LH.
To further study the role of GnRH2 and its receptor in pigs, 
our laboratory generated a GnRHR2 knockdown swine line (53). 
These animals ubiquitously express short hairpin RNA targeting 
the porcine GnRHR2. Consequently, testicular GnRHR2 mRNA 
levels were reduced by 70% in adult males compared with lit-
termate control animals (53). During pubertal development, 
GnRHR2 knockdown boars had smaller testes (Figure  8A) 
despite a normal body weight (Figure  8B), implying impaired 
testicular function. Moreover, testosterone concentrations tended 
to be lower (Figure 8C) in transgenic versus littermate control 
males, yet LH concentrations were unaffected [Figure 8D; (53)]. 
These results support our hypothesis that activation of GnRHR2 
on porcine Leydig cells stimulates LH-independent testosterone 
secretion. These swine represent the first genetically engineered 
animal model to study the function of GnRH2 and its receptor 
in mammals and are currently being utilized to identify the 
molecular mechanisms linking GnRHR2 and steroidogenesis in 
male pigs. Given that testosterone and its metabolites govern male 
fertility (e.g., sex differentiation, reproductive tract maintenance, 
libido, spermatogenesis, and accessory sex gland function), 
GnRH2 and its receptor are novel molecular targets to enhance 
reproductive efficiency in swine.
Female Reproduction
Although GnRH2 and its receptor are expressed within female 
reproductive tissues (Table 3), few studies have directly examined 
the role of the GnRH2/GnRHR2 system in the female. Several 
lines of evidence suggest that GnRH2 and its receptor are novel 
regulators of placental function, implantation, and ovarian 
steroidogenesis. GnRH2 is produced by the human placenta in 
a pulsatile manner and is six times more stable than GnRH1 
when exposed to placental enzymes (70). GnRH2 stimulated the 
production of hCG in human placental explants (70, 160–162), 
whereas GnRH1 treatment did not (70). Moreover, a high affin-
ity receptor specific for GnRH2 (70), as well as immunoreactive 
GnRHR2 (163), have been detected in the human placenta.
When compared with GnRH1, GnRH2 potently enhanced 
invasion of human trophoblasts (84) through extracellular matrix 
remodeling (164). Notably, antagonizing or knocking down 
GnRHR1 abrogated GnRH1-mediated effects on trophoblast cells 
but did not influence GnRH2-stimulated invasion (84, 165, 166). 
In addition, GnRH2 (mRNA and protein) was found in the uterine 
endometrium (stromal and glandular epithelial cells) of women 
during all phases of the menstrual cycle, although GnRH2 pro-
duction increased during the secretory phase, indicative of a role 
in implantation (67). The GnRHR2 may be produced in human 
endometrium as well given that both high and low affinity-binding 
sites for GnRH1 were identified in human endometrial cancer 
cells (167). Given that GnRH1 binds GnRHR2 with 15-fold less 
affinity (29), the low affinity-binding site for GnRH1 detected in 
this study may be the GnRHR2. Indeed, others have demonstrated 
that immunoreactive GnRHR2 is present in human endometrial 
adenocarcinomas (163). Treatment of rhesus macaques with a 
GnRHR2 agonist near ovulation conferred contraceptive actions 
in 100% of females; this effect was not mediated by the inhibition 
of progesterone secretion (168). In a subsequent study, pregnancy 
was prevented in all females receiving GnRH2 treatment, whereas 
62.5% of saline-treated controls became pregnant. Interestingly, 
the low doses of GnRH2 (2–8  μg/day) inhibited secretion of 
progesterone, whereas high doses (16–32 μg/day) had no effect 
(169). Nevertheless, pregnancy was prevented in all treatment 
groups, indicating that the contraceptive activity of GnRH2 is not 
confined to the suppression of progesterone production alone.
FiGURe 8 | GnRHR2 knockdown (KD) swine have smaller testes and reduced serum testosterone concentrations but similar body weights and circulating 
luteinizing hormone (LH) levels compared with littermate control animals during pubertal development. At 40, 100, 150, 190, 225, and 300 days of age, blood was 
collected from GnRHR2 knockdown (n = 10) and littermate control (n = 7) males; at the same time points, body weight and predicted testis volume were measured. 
Serum testosterone and LH concentrations were determined by radioimmunoassay. Data are presented as the Least Squares Means (±SEM). The P-value for the 
main effect of line is indicated. (A) Predicted testis volume, (B) body weight, (C) serum testosterone concentrations, and (D) serum LH concentrations. Adapted 
from Desaulniers et al. (53); no permission is required from the copyright holder.
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In other species, GnRH2 appears to modulate secretion 
of progesterone as well. Kang et  al. (58) reported that GnRH2 
inhibited basal and hCG-stimulated progesterone secretion from 
human granulosa-luteal cells. In the baboon, GnRH2 is present 
in the ovary and released from granulosa cells in vitro. Exogenous 
GnRH2 administration suppressed production of progesterone 
from cultured granulosa cells by 75% (60), whereas GnRH1 failed 
to suppress progesterone release. Binding kinetics indicated two 
binding sites for GnRH2, a high and a low affinity site, compared 
with only one binding site for GnRH1, suggesting the presence of 
a GnRH2-specific receptor in the baboon ovary (60). Collectively, 
these data are compelling; however, more studies are needed to 
determine how GnRH2 and its receptor impact female reproduc-
tion in mammals. Toward this end, research in our laboratory is 
currently underway to define the role of GnRH2 and its receptor 
in reproductive function of the female pig.
Cancer
It is well established that GnRH1 and its receptor are expressed in 
cancer cells derived from reproductive tissues and administration of 
GnRH1 analogs inhibits their proliferation (51, 170, 171). GnRH2 
and its receptor may also influence the progression of reproductive 
cancers, given that both are expressed in cancer cells (Table 4) and 
tumors derived from reproductive tissues (38, 44, 51, 170, 171). 
Growing evidence indicates that treatment of cancer cells with 
GnRH2 analogs inhibits their proliferation. This has been dem-
onstrated in prostate (54, 172), ovarian, breast, and endometrial 
cancer cells (38, 40, 170, 171). Interestingly, GnRH2 appears to 
have a more potent anti-proliferative effect than GnRH1 (51). The 
cellular mechanisms by which GnRH2 mediates this effect have 
been the subject of recent research efforts. Treatment of breast 
cancer cells with either GnRH1 or GnRH2 inhibited ribosomal 
phosphoproteins, which are needed for proper protein translation 
and cell proliferation (38). GnRH2 also increased metalloprotein-
ase production, key regulators of tumor invasion, in ovarian cancer 
cells (173). In addition, treatment with a GnRH2 agonist reduced 
cell proliferation and inhibited the mitogenic effects of epidermal 
growth factor in human endometrial and ovarian cancer cells 
(120). In addition, GnRH2 and its receptor may have emerging 
roles in the modulation of cell proliferation via extracellular vesi-
cles. For example, glioblastoma-derived microvesicles increased 
proliferation of tumor cells in vitro; the same microvesicles were 
also found to carry GnRH2, GnRH1, GnRHR2, and GnRHR1 
mRNA (174). Thus, GnRH/GnRHR transcripts packaged in 
extracellular vesicles could be an unexploited mechanism to affect 
tumor progression in humans.
In addition to anti-proliferative actions, GnRH2 analogs 
may also exert pro-apoptotic effects on cancer cells. Treatment 
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with several GnRHR2 antagonists inhibited growth of human 
endometrial and ovarian cancer cells in  vitro and in  vivo via 
caspase 3-dependent mechanisms (175); a different GnRHR2 
antagonist (SN09-2) induced apoptosis in prostate cancer cells 
(172). Likewise, GnRH2 can increase apoptosis via the caspase-
dependent pathway in human granulosa cells (176). In breast can-
cer cells, yet another GnRHR2 antagonist induced apoptotic cell 
death in vitro and in vivo (177). In addition to anti-proliferative 
and pro-apoptotic effects, GnRH2 might also regulate cellular 
autophagy. Human prostate cancer cells treated with a GnRHR2 
antagonist (Trptorelix-1) displayed increased mitochondrial dys-
function as well as autophagosome formation (178). These cells 
had decreased Akt phosphorylation and increased c-Jun phos-
phorylation, additional hallmarks of cell autophagy. In numerous 
cases, the effects of GnRH2 on cancer cells were not mediated 
through the GnRHR1, implying a role for human GnRHR2 
(50, 52, 120, 177). Thus, GnRH2 and possibly its receptor, regulate 
cancer cell proliferation/survival and represent emerging targets 
for the development of new cancer therapies.
CONCLUSiON
GnRHs are ancient peptides which may have first functioned 
to directly regulate the gonads before evolving into specialized 
modulators of gonadotropin secretion. GnRH2 is the most 
ancient of the GnRHs and has been completely conserved from 
boney fish to man, signifying a critical biological role. Moreover, 
GnRH2 is structurally unique from GnRH1, which promotes 
its stability and half-life. A highly selective receptor specific for 
GnRH2 is also produced in mammals. The GnRHR2 is dissimilar 
from GnRHR1, containing an intracytoplasmic tail and eliciting 
divergent cell signaling cascades. The genes for GnRH2 and/or 
GnRHR2 have been deleted or inactivated in many species, but 
both are functional in old world monkeys, musk shrews and pigs, 
implying an essential role in these animals. Moreover, evidence 
continues to suggest the presence of GnRHR2 in humans despite 
apparent coding errors in the gene. Data from numerous species 
(including humans) demonstrates that GnRH2 and its receptor 
are ubiquitously expressed. Notably, both are produced in low 
abundance in regions of the brain associated with gonadotropin 
secretion and highly expressed in peripheral reproductive organs. 
Thus, GnRH2 and its receptor are both structurally and function-
ally distinct from their classical counterparts.
Contrary to their name, GnRH2 and GnRHR2 are not 
physiological stimulators of gonadotropin secretion in mammals. 
Instead, GnRH2 and its receptor have been implicated in various 
functions, mostly pertaining to mammalian reproduction. The 
first defined function of GnRH2 and its receptor was the modula-
tion of sexual behavior, based on nutritional status, in females. 
Within peripheral tissues, GnRH2 and its receptor are important 
regulators of reproductive organs in both males and females. For 
example, GnRH2 and its receptor directly regulate steroidogenesis 
within the porcine testis. In the female, GnRH2 and its receptor 
may mediate placental function, implantation, and ovarian steroi-
dogenesis. Furthermore, both GnRH2 and GnRHR2 are expressed 
in human reproductive tumors and are emerging targets for cancer 
treatment. Therefore, GnRH2 and its receptor are critical modula-
tors of reproductive function in mammals, albeit via a divergent 
mechanism from the classical GnRH1 and GnRHR1 interaction. 
More work is needed to better understand the importance of local-
ized regulation by the GnRH2/GnRHR2 system, but its contribu-
tion to mammalian reproduction is unequivocal.
Despite these data, the ubiquitous nature of GnRH2 and 
GnRHR2 suggests that many more biological functions remain 
undefined. The deletion of the GnRH2 and GnRHR2 genes from 
the rat and mouse has undoubtedly inhibited the study of this 
system in a widely available and economical laboratory animal. 
However, the recent development of a GnRHR2 knockdown 
swine line provides an essential animal model to explore the 
functions of GnRH2 and its receptor in mammals. Given the 
recent discovery of the GnRH2 and GnRHR2 genes in numerous 
mammalian species, this system may be physiologically relevant 
and unexploited in a wide range of species.
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